|
Cost-effectiveness of a 14-gene risk score assay to target adjuvant chemotherapy in early stage non-squamous non-small cell lung cancer |
Roth JA, Billings P, Ramsey SD, Dumanois R, Carlson JJ |
|
|
Record Status This is an economic evaluation that meets the criteria for inclusion on NHS EED. Bibliographic details Roth JA, Billings P, Ramsey SD, Dumanois R, Carlson JJ. Cost-effectiveness of a 14-gene risk score assay to target adjuvant chemotherapy in early stage non-squamous non-small cell lung cancer. Oncologist 2014; 19(5): 466-476 Indexing Status Subject indexing assigned by NLM MeSH Aged; Antineoplastic Agents /therapeutic use; Antineoplastic Combined Chemotherapy Protocols /economics /therapeutic use; Carcinoma, Non-Small-Cell Lung /drug therapy /genetics /mortality /surgery; Chemotherapy, Adjuvant /economics; Cisplatin /therapeutic use; Cost-Benefit Analysis; Health Care Costs; Humans; Lung Neoplasms /drug therapy /genetics /mortality /surgery; Molecular Diagnostic Techniques; Neoplasm Recurrence, Local /economics; Quality-Adjusted Life Years; Risk; Vinblastine /analogs & derivatives /therapeutic use AccessionNumber 22014017198 Date bibliographic record published 09/10/2014 |
|
|
|